These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30377997)

  • 21. Prognostic value of 123I-metaiodobenzylguanidine in patients with various heart diseases.
    Nagamatsu H; Momose M; Kobayashi H; Kusakabe K; Kasanuki H
    Ann Nucl Med; 2007 Nov; 21(9):513-20. PubMed ID: 18030583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of 5 Minutes
    Frantellizzi V; Ricci M; Farcomeni A; Pontico M; Pani A; Vincentis G
    Curr Radiopharm; 2020; 13(2):120-129. PubMed ID: 31985388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction.
    Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
    Heart; 2011 Jan; 97(1):20-6. PubMed ID: 21062772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death.
    Wakabayashi T; Nakata T; Hashimoto A; Yuda S; Tsuchihashi K; Travin MI; Shimamoto K
    J Nucl Med; 2001 Dec; 42(12):1757-67. PubMed ID: 11752070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iodine-123-metaiodobenzylguanidine scintigraphy in risk stratification of sudden death in heart failure.
    Martins da Silva MI; Vidigal Ferreira MJ; Morão Moreira AP
    Rev Port Cardiol; 2013 Jun; 32(6):509-16. PubMed ID: 23731734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.
    Nakata T; Nakajima K; Yamashina S; Yamada T; Momose M; Kasama S; Matsui T; Matsuo S; Travin MI; Jacobson AF
    JACC Cardiovasc Imaging; 2013 Jul; 6(7):772-84. PubMed ID: 23845574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study.
    Paolillo S; Rengo G; Pagano G; Pellegrino T; Savarese G; Femminella GD; Tuccillo M; Boemio A; Attena E; Formisano R; Petraglia L; Scopacasa F; Galasso G; Leosco D; Trimarco B; Cuocolo A; Perrone-Filardi P
    Diabetes Care; 2013 Aug; 36(8):2395-401. PubMed ID: 23530014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA.
    O'Day K; Levy WC; Johnson M; Jacobson AF
    Appl Health Econ Health Policy; 2016 Jun; 14(3):361-73. PubMed ID: 26975999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure.
    Kuramoto Y; Yamada T; Tamaki S; Okuyama Y; Morita T; Furukawa Y; Tanaka K; Iwasaki Y; Yasui T; Ueda H; Okada T; Kawasaki M; Levy WC; Komuro I; Fukunami M
    Am J Cardiol; 2011 Apr; 107(8):1185-90. PubMed ID: 21349482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac sympathetic innervation assessed with (123)I-MIBG retains prognostic utility in diabetic patients with severe left ventricular dysfunction evaluated for primary prevention implantable cardioverter-defibrillator.
    García-González P; Fabregat-Andrés Ó; Cozar-Santiago P; Sánchez-Jurado R; Estornell-Erill J; Valle-Muñoz A; Quesada-Dorador A; Payá-Serrano R; Ferrer-Rebolleda J; Ridocci-Soriano F
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):74-80. PubMed ID: 26514320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models.
    Jain KK; Hauptman PJ; Spertus JA; Kennedy KF; Bateman TM; Jacobson AF; Stolker JM
    J Card Fail; 2014 Aug; 20(8):577-83. PubMed ID: 24951931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study.
    Narula J; Gerson M; Thomas GS; Cerqueira MD; Jacobson AF
    J Nucl Med; 2015 Jul; 56(7):1011-8. PubMed ID: 26069309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of aging on cardiac sympathetic innervation measured by
    Rengo G; Pagano G; Vitale DF; Formisano R; Komici K; Petraglia L; Parisi V; Femminella GD; de Lucia C; Paolillo S; Cannavo A; Attena E; Pellegrino T; Dellegrottaglie S; Memmi A; Trimarco B; Cuocolo A; Filardi PP; Leosco D; Ferrara N
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2392-2400. PubMed ID: 27287990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional Cardiac Sympathetic Nervous System Evaluation Using 123I-mIBG SPECT in Patients with Heart Failure.
    Iqbal B; Currie G; Kiat H
    J Med Imaging Radiat Sci; 2018 Dec; 49(4):397-405. PubMed ID: 30514557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure.
    Veltman CE; Boogers MJ; Meinardi JE; Al Younis I; Dibbets-Schneider P; Van der Wall EE; Bax JJ; Scholte AJ
    Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1599-608. PubMed ID: 22790878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of cardiac metaiodobenzylguanidine imaging and QRS duration in implantable cardioverter defibrillator patients with and without heart failure.
    Kawasaki M; Yamada T; Morita T; Furukawa Y; Tamaki S; Iwasaki Y; Kikuchi A; Kawai T; Seo M; Hirota Kida ; Sakata Y; Fukunami M
    Int J Cardiol; 2019 Dec; 296():164-171. PubMed ID: 31371118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Quantitative analysis of 123I-metaiodobenzylguanidine myocardial imaging: assessment of its usefulness in patients with congestive heart failure].
    Narita M; Kurihara T; Murano K; Usami M; Honda M
    Kaku Igaku; 1994 Apr; 31(4):347-58. PubMed ID: 8196231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure.
    Jacobson AF; White S; Travin MI; Tseng C
    Nucl Med Commun; 2017 Feb; 38(2):141-148. PubMed ID: 27861299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of outcome in patients with de novo diagnosis of heart failure with reduced ejection fraction: Role of combined myocardial and lung Iodine-123 Meta-Iodobenzylguanidine imaging.
    Silverio A; Polito MV; Pace L; D'Auria F; Vitulano G; Scarano M; Citro R; Galasso G; Piscione F
    J Nucl Cardiol; 2021 Feb; 28(1):72-85. PubMed ID: 30761483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a
    Komici K; Bencivenga L; Paolillo S; Gargiulo P; Formisano R; Assante R; Nappi C; Marsico F; D'Antonio A; De Simini G; Cittadini A; Vitale DF; Cuocolo A; Filardi PP; Ferrara N; Rengo G
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(7):1713-1721. PubMed ID: 31872281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.